Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) CFO Alan Fuhrman bought 9,500 shares of the firm's stock in a transaction on Wednesday, October 30th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $152,000.00. Following the transaction, the chief financial officer now owns 12,849 shares in the company, valued at approximately $205,584. This represents a 200.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Tyra Biosciences Stock Down 1.7 %
Shares of Tyra Biosciences stock opened at $16.39 on Friday. The company has a 50 day moving average of $22.51 and a 200-day moving average of $19.87. Tyra Biosciences, Inc. has a 1-year low of $10.60 and a 1-year high of $29.60.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.09. As a group, equities analysts forecast that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.
Analyst Upgrades and Downgrades
The latest trend in real estate
From Pacaso | Ad
These vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, they’re being transformed into fully utilized assets. And there’s one company that’s leading the charge – already welcoming over 1,500 happy homeowners into their co-ownership family, earning $100M in gross profits along the way.
Now, for the first time, this innovative company is opening its doors to public investors. Want to learn more about co-ownership and its potential? Check them out – but be aware: their share price is set to change December 5, so you don’t have long to maximize your stake.
Don’t miss your chance to maximize your stake in this co-ownership revolution.
A number of research analysts have issued reports on TYRA shares. Piper Sandler started coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They set an "overweight" rating and a $33.00 target price on the stock. Oppenheimer increased their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an "outperform" rating in a research report on Thursday, September 19th. HC Wainwright increased their target price on shares of Tyra Biosciences from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Monday, October 28th. Wedbush restated an "outperform" rating and set a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. Finally, Bank of America raised shares of Tyra Biosciences from a "neutral" rating to a "buy" rating and upped their price target for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences has a consensus rating of "Buy" and an average price target of $31.40.
Read Our Latest Report on TYRA
Hedge Funds Weigh In On Tyra Biosciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new position in Tyra Biosciences in the 3rd quarter valued at approximately $311,000. HighVista Strategies LLC bought a new position in Tyra Biosciences in the 2nd quarter valued at approximately $257,000. Rhumbline Advisers lifted its stake in Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company's stock valued at $377,000 after purchasing an additional 2,574 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Tyra Biosciences by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company's stock valued at $929,000 after purchasing an additional 14,352 shares during the last quarter. Finally, Oppenheimer & Co. Inc. bought a new position in Tyra Biosciences in the 1st quarter valued at approximately $977,000. Institutional investors own 84.14% of the company's stock.
Tyra Biosciences Company Profile
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
